Caixin
Sep 03, 2020 01:37 PM
BUSINESS & TECH

Chinese Investor Hunting for Next Moutai Wins Big on Cocktails

A bartender pours a baijiu-based cocktail at Bar Lumos, which serves 40 different brands of baijiu, in New York, U.S., on Sept. 27, 2016. Photo: Bloomberg
A bartender pours a baijiu-based cocktail at Bar Lumos, which serves 40 different brands of baijiu, in New York, U.S., on Sept. 27, 2016. Photo: Bloomberg

(Bloomberg) — In his search for the next Kweichow Moutai Co., Zhu Liang discovered a cocktail maker that has helped his flagship fund post a 72% return this year.

One of the most successful among the roughly 10 stocks Zhu holds is Shanghai Bairun Investment Holding Group Co., which makes pre-mixed cocktails, fragrances as well as flavors. The stock has more than doubled this year after nearly tripling in 2019 when the chief investment officer at Shanghai Danyi Investment Management Co. first bought it.

Zhu’s firm has a pool of 80 to 100 stocks to watch closely, with about 800 million yuan ($117 million) of assets under management. Zhu’s flagship fund has returned 185% since its inception in January 2018, according to fund tracker Shenzhen PaiPaiWang Investment & Management Co.

His strategy is to identify stocks that he thinks will offer high growth over a long period, and he references Moutai and Jiangsu Hengrui Medicine Co. as examples of stocks that were successful for investors who got in early. Both have seen their market value increase by more than 10 times over the past decade.

“Many long-term bull stocks have emerged in the consumer and technology sectors in the past, but the chances of that happening in finance and industrial sectors are low,” said Zhu. “That’s why I focus on industries that are more likely to foster long-term bull stocks.”

Other holdings include medical laboratory operator Guangzhou Kingmed Diagnostics Group Co., which has also doubled this year. Zhu said he invested in some pharmaceutical stocks recently, declining to elaborate on details.

China’s stock market has outperformed most global major indexes this year, amid signs of the economy’s recovery from the Covid-19 pandemic and supportive market policies from the government that have encouraged riskier trading. The benchmark CSI 300 Index is up 18% this year, with consumer staples, health care and information technology sectors the best performers.

That’s led to some concerns over high valuations, but Zhu says there are still bargains to be found, especially laggards in sectors such as home appliances and the dairy industry.

“There are some very good stocks in these industries that have underperformed due to short-term headwinds,” he said. “We are keeping a close eye on the inflection point to come.”

Support quality journalism in China. Subscribe to Caixin Global starting at $0.99.

Contact editor Yang Ge (geyang@caixin.com)

loadingImg
You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code